
Investments
Our Philosophy
Impact Propelling a Healthier World
Building a global ecosystem for change
Adding just one year of healthy lifespan translates into trillions of dollars in increased productivity and GDP. Achieving this vision requires collaboration and bringing together academicians, investigators, entrepreneurs, the biopharmaceutical industry, healthcare providers, policymakers, and regulators to translate discoveries into real-world, safe, and effective solutions.
An inclusive approach
As a mission-driven organization, we take a pragmatic and inclusive approach, operating internationally without being bound to specific markets or purely philanthropic returns. We aim to extend healthspan for everyone in a way such that there is more equity and accessibility to therapies that help people live healthier, longer. At every step, we are guided by the highest standards of scientific integrity and ethics, ensuring that progress benefits humanity equitably and responsibly.
Our Strategy
Driving impact through innovation
At Hevolution, we are driving the transition from today’s reactive “sick care” model to proactive healthcare through research and development that meets the highest international standards of science, ethics, and integrity. By increasing the breadth of knowledge in aging biology and translating discoveries into safe and effective solutions, we support existing companies and incubate new ones globally to create novel therapies.
A unique pragmatic and collaborative framework
We work closely with our world-class internal science and grantmaking teams to define broad scientific and investment strategies. Every investment is deeply diligent towards both its scientific rigor and commercial potential. As active venture investors, we collaborate alongside industry leaders, company founders, and other ecosystem players to ensure that real solutions with measurable impact are developed for patients and all stakeholders involved.
Long-term impact investment with a focus on aging biology
Our focus is on early-stage, programmatic investments in biotech companies that address the mechanisms of aging biology rather than specific diseases. However, we recognize the importance of treating high unmet medical needs today as a pathway to understanding aging at its core. Additionally, through our Breakthrough Innovation Alliance (BIA), we incubate companies with transformational ideas, ensuring they have the expertise, funding, and support to advance from ideation to commercialization.
Our Portfolio
Clinical-stage platform company developing first-in-class medicines targeting senescent cells that drive aging and disease.
Clinical-stage platform company developing “tunable” genetic medicines for chronic and age-related conditions.
Clinical-stage Swiss biotech at the vanguard of mitochondrial therapeutics – developing mitophagy inducers for age-related diseases.
Breakthrough Innovation Alliance (BIA Venture)

The BIA is our hands-on initiative to create and support companies advancing healthy aging. Unlike traditional accelerators, we convene a unique consortium of entrepreneurs-in-residence and pair capital with the practical mentorship and specialized expertise of biopharma leaders, VC investors, academics and CROs – together identifying and backing the best ideas in healthspan.



